A Variant of the Breast Cancer Type 2 Susceptibility Protein (BRC) Repeat Is Essential for the RECQL5 Helicase to Interact with RAD51 Recombinase for Genome Stabilization*§

M. Nurul Islam1§, Nicolas Paquet5, David Fox III6, Eloise Dray6, Xiaofeng Zheng9, Hannah Klein8, Patrick Sung51, and Weidong Wang1,2

From the 1Laboratory of Genetics, NIA, National Institutes of Health, National Institutes of Health Biomedical Research Center, Baltimore, Maryland 21224, the 2Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, Connecticut 06520, and the 3Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York 10016

Background: The BRC repeat is essential for BRCA2 to bind RAD51 and promote homologous recombination. Results: A BRC repeat variant is essential for RECQL5 to bind RAD51 and suppress homologous recombination. Conclusion: The BRC repeat can be utilized to either promote or suppress homologous recombination. Significance: Discovery of multiple functions of the BRC repeat is important for understanding regulation of homologous recombination.

The BRC repeat is a structural motif in the tumor suppressor BRCA2 (breast cancer type 2 susceptibility protein), which promotes homologous recombination (HR) by regulating RAD51 recombinase activity. To date, the BRC repeat has not been observed in other proteins, so that its role in HR is inferred only in the context of BRCA2. Here, we identified a BRC repeat variant, named BRCv, in the RECQL5 helicase, which possesses anti-recombinase activity in vitro and suppresses HR and promotes cellular resistance to camptothecin-induced replication stress in vivo. RECQL5-BRCv interacted with RAD51 through two conserved motifs similar to those in the BRCA2-BRC repeat. Mutations of either motif compromised functions of RECQL5, including association with RAD51, inhibition of RAD51-mediated D-loop formation, suppression of sister chromatid exchange, and resistance to camptothecin-induced replication stress. Potential BRCvs were also found in other HR regulatory proteins, including Srs2 and Sgs1, which possess anti-recombinase activities similar to that of RECQL5. A point mutation in the predicted Srs2-BRCv disrupted the ability of the protein to bind RAD51 and to inhibit D-loop formation. Thus, BRC is a common RAD51 interaction module that can be utilized by different proteins to either promote HR, as in the case of BRCA2, or to suppress HR, as in RECQL5.

Homologous recombination (HR) is critical for the error-free repair of chromosomal lesions, such as DNA double strand breaks, and also for the recovery of damaged replication forks (1, 2). During meiosis, HR generates crossovers among homologous chromosomes to ensure their proper segregation at the first meiotic division (1, 3). Thus, HR is indispensable for the maintenance of genome integrity and meiotic chromosome segregation (4). In fact, defects in HR can increase cancer and failed meiosis (4). On the other hand, untimely and inappropriate HR can cause gross chromosome rearrangements, including translocations, deletions, and inversions, with potentially mutagenic or oncogenic consequences (2, 4). Therefore, HR is tightly controlled in cells by a variety of pro- and anti-recombination regulatory mechanisms.

Human BRCA2 and its orthologs are an important positive regulatory element for HR (5–7). BRCA2 directly interacts with RAD51 recombinase and recruits it to double strand breaks. BRCA2 promotes the formation of the RAD51-ssDNA nucleoprotein filament that pairs with and invades a homologous DNA duplex to initiate homologous DNA repair. Moreover, BRCA2 modulates the DNA binding selectivity of RAD51 to stimulate strand exchange (8, 9). The primary RAD51 interaction domain in BRCA2 and its orthologs consists of a varying number of the BRC repeat, a module of ~35 amino acid residues (10, 11). The BRCA repeat directly associates with RAD51 or RAD51-DNA filaments, regulates the DNA binding activity of RAD51, enhances the exchange of the ssDNA-binding factor replication protein A (RPA) by RAD51 on ssDNA, and promotes RAD51-dependent homologous DNA pairing (8, 9, 12, 13). Structural and functional analyses have revealed that the BRCA repeat harbors two motifs, referred to as motif 1 and motif 2, which are separated by a linker sequence (11, 14). Motif 1

* This work was supported, in whole or in part, by National Institutes of Health, NIA, Intramural Research Program Grant Z01 AG000657-09 (to W. W.) and National Institutes of Health Grants ES016532 and ES015252 (to P. S.).

§ This article contains supplemental Figs. S1–S3.

1 To whom correspondence may be addressed: Dept. of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT 06520. Tel.: 203-785-4569; Fax: 203-785-6464; E-mail: patrick.sung@yale.edu.

2 To whom correspondence may be addressed: Laboratory of Genetics, NIA, National Institutes of Health, NIBiomedical Research Center, Rm. 10B113, 251 Bayview Blvd., Baltimore, MD 21224. Tel.: 410-558-8334; Fax: 410-558-8331; E-mail: wangw@grc.nia.nih.gov.

The abbreviations used are: HR, homologous recombination; RPA, replication protein A; SCE, sister chromatid exchange; Pol, polymerase; IP, immunoprecipitation; IP-Western, immunoprecipitation-coupled Western blot; CPT, camptothecin; Ni-NTA, nickel-nitrilotriacetic acid.
binds the oligomerization interface of RAD51 to regulate RAD51 filament assembly, whereas motif 2 binds a separate region of RAD51, and a functional BRC repeat requires the two motifs working in tandem pairs (14).

To date, the BRC repeat has not been discovered in any other proteins, but we report here its presence in RECQL5, where it also regulates HR. RECQL5 is one of five RecQ-like DNA helicases in mammalian cells (15, 16). Genetic studies in mice and chicken DT40 cells have implicated RECQL5 in the suppression of HR, including inhibition of sister chromatid exchange (SCE) (17, 18), in the preservation of genome integrity upon genotoxic stress (19) and in cancer avoidance (20). RECQL5 directly interacts with RAD51 and inhibits RAD51-mediated homologous DNA pairing by dismantling the RAD51 presynaptic filament assembled on ssDNA (20, 21). A previous study has mapped a RAD51-interacting region between residues 654 and 725 of RECQL5 and shown that several residues within this region are important for binding and regulation of RAD51 recombinase in vitro and for HR regulation in vivo (21). However, the region was not defined as a recognizable domain. Here, we show that the RAD51 interaction domain in RECQL5 consists of two motifs with a strong resemblance to the conserved motifs found in the BRCA2-BRC repeats. We have named this RECQL5 domain BRCv (BRC variant) because it also harbors notable differences from the BRC repeats in BRCA2. Importantly, we demonstrate that both motifs of BRCv are required for RECQL5 to interact with RAD51, to inhibit RAD51-mediated homologous DNA pairing, to suppress SCE, and to tolerate replication stress. Sequence-based comparisons reveal that potential BRCvs are present in other HR regulatory proteins, suggesting that the BRC repeat and its variants may be employed by many proteins in the regulation of HR.

**EXPERIMENTAL PROCEDURES**

**Cell Culture**—Chicken DT40 cell lines were maintained in RPMI medium (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum, 1% chicken serum, 1.5% penicillin-streptomycin (Invitrogen), and 10 mM Hepes (pH 7.9). HEK-293 cells were grown in DMEM containing 10% fetal bovine serum.

**Antibodies**—RAD51 (H-92) and RAD51 (ab63801) antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) and Abcam, respectively. Anti-FLAG M2 and RNA polymerase II (Pol II) (ARNA-3) monoclonal antibodies were obtained from Sigma and Fitzgerald, respectively.

**Protein Purification**—Wild-type and mutant forms of human RECQL5 were expressed in *Escherichia coli* and purified as described previously (20). Human RAD51 K133R, RPA, and HOP2-MND1 complex were purified according to previously published protocols (22, 23). Wild type and mutant forms of Srs2 were expressed in *E. coli* and purified as described (24, 25). Yeast Rad51 protein was expressed in yeast cells and purified as described (26).

**Immunoprecipitation**—RecQ5-associated complexes were isolated from total cell lysate of HEK-293 cells transiently expressing FLAG-tagged RECQL5 (FRECQL5). Cell pellets were suspended in three volumes of lysis buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 5 mM MgCl2, and 0.5% Nonidet P-40) containing 1 mM PMSE, 1 mM DTT, and protease inhibitor mixture. FLAG immunoprecipitation (IP) was done according to the manufacturer’s protocol (Sigma). In brief, cell lysates were diluted three times with lysis buffer and incubated with anti-FLAG M2-agarose affinity gel for at least 12 h at 4 °C. The resin was washed three times for 10 min each with lysis buffer and then treated with the FLAG peptide to elute proteins. The eluate was subjected to immunoblotting.

**Affinity Pull-down**—His6-tagged wild type or mutant Srs2 was incubated with yeast Rad51 in 30 μl of buffer (25 mM Tris-HCl, pH 7.5, 0.01% Igepal, 1 mM 2-mercaptoethanol, and 10 mM imidazole) containing 100 mM KCl for 30 min at 4 °C and then mixed with 10 μl of Ni-NTA-agarose (Qiagen) for 2 h at 4 °C to capture the tagged Srs2 and Rad51. The resin was washed three times with 50 μl of the same buffer and then treated with 20 μl of 2% SDS to elute proteins. The supernatant, last wash, and SDS eluate (10 μl each) were analyzed by SDS-PAGE.

**ATPase Assay**—The ATPase assay was carried out as described (20). Briefly, RECQL5 or one of the indicated RECQL5 mutants (25 nM) was incubated with dX174 ssDNA (75 μM nucleotides) and 1.5 mM [γ-32P]ATP for the indicated times. Analysis was done by thin layer chromatography (20).

**D-loop Assay**—This was conducted at 37 °C as described (20), by incubating the RAD51-K133R protein (1 μM) with radioactively labeled 90-mer oligonucleotide D1 (3 μM nucleotides) for 5 min, followed by the incorporation of RPA (135 nM) together with RECQL5 or the indicated RECQL5 mutant (25 nM) and a 5-min incubation. Then HOP2-MND1 (300 nM) and pBlue-script replicative form I DNA (50 μM base pairs) were added to complete the reaction. After 10 min of incubation, the reaction mixtures were deproteinized and analyzed, as described (20). The D-loop assay for wild type and mutant forms of Srs2 was conducted according to Ref. 24.

**Complementation Analyses**—Complementation analyses were done as described previously (27) with some modifications. In brief, FLAG-tagged RECQL5 constructs were generated by using a QuickChange multisite-directed mutagenesis kit and transfected into *BLM−/−/RecQ5−/−* chicken DT40 cells by using nucleofection solution. 1 × 106 cells in pellets were suspended into 100 μl of nucleofection solution, and 2–5 μg of DNA was then added to the suspended solutions. Due to the low transfection efficiency, each construct was digested with XhoI, and the linearized plasmids were used for transfection. Transfected solutions were incubated for 24 h in a 6-well plate with 2.0 ml of medium. Stable clones were isolated from the primary transfectant pools using limiting dilution into 96-well plates and selection for resistance to zeocin.

**SCE Assay**—The SCE assay followed the published protocol (27, 28) with minor modifications. In brief, cell cultures were grown through two cell cycles in the presence of 10 μM 5-bromodeoxyuridine (BrdU). Colcemid was added to a final concentration of 0.1 μg/ml to accumulate mitotic cells 2 h prior to the harvesting of cells. Harvested cells were then treated with 75
mm KCl for 20 min at room temperature and then fixed with 3:1 (v/v) methanol-glacial acetic acid. The fixed cell suspension was dropped onto a glass slide and air-dried. The cells on the slides were incubated with 10 \( \mu \)g of Hoechst 33258/ml in 50 mM phosphate buffer (pH 6.8) for 20 min and rinsed with MacIlvaine solution. The cells were exposed to UV for 60 min and then incubated in 2× SSC at room temperature for 60 min. The cells were finally stained with 3% Giemsa solution for 20–40 min and examined under a light microscope.

Camptothecin (CPT) Sensitivity Assay—This assay was done as described (27).

Homology Modeling—The homology model was generated as described previously (27, 29, 30).

RESULTS

**RECQL5 Interacts with RAD51 through a Conserved Region**—A RAD51-interacting region has been previously identified in RECQL5 by an in vitro assay using a series of RECQL5 fragments (21). We confirmed and extended the previous analysis in vivo by expressing a series of FLAG-tagged RECQL5 fragments (Fig. 1A) in HEK-293 cells and performing immunoprecipitation-coupled Western blot (IP-Western) to identify the RAD51 interaction domain. This strategy has been previously used to identify the KIX and SRI domains as the Pol II interaction domains of RECQL5 (27). We found that the region (residues 621–900) between the KIX and SRI domains is both nec-
ecessary and sufficient for RAD51 association (Fig. 1, A and B, lane 8). Because RAD51 is highly conserved in evolution, it seemed likely that its binding residues in RECQL5 should also be well conserved. Therefore, we mutagenized several conserved residues within this region (Fig. 1C) and found that mutant B (F666A/Q667A) substantially reduced RAD51 association, whereas mutant A (K651A/K653A/R654A) and mutant C (K750A/Q752A) retained normal association (Fig. 1, C and D). Thus, the region containing Phe-666 and Glu-667 is required for RAD51 association, in agreement with the previous in vitro data indicating that Phe-666 and residues between positions 652 and 674 are required for RAD51 interaction (21). We noted that although mutant B has reduced association with RECQL5, it retained normal association with Pol II (Fig. 1D), indicating that RECQL5-RAD51 association is independent of RECQL5-Pol II interactions.

A BRC Repeat Variant Is Present in the RAD51 Interaction Domain of RECQL5—Sequence analysis revealed that the RAD51 interaction domain of RECQL5 contains two conserved motifs that are either identical or similar to those previously described in the BRC repeat of BRCA2 (Fig. 2A) (14). For example, the consensus sequence of motif 1 in RECQL5, FX(T/S)A, is identical to the corresponding sequence of the BRC repeat (FXXA) (Fig. 2A). In addition, the motif 2 sequence of RECQL5, LLDE, is also similar to the consensus sequence of motif 2 of the BRC repeat (hhxA, where “h” represents a hydrophobic and “a” represents an acidic residue). Based on these observations, we have named the RECQL5 region that encompasses the two conserved motifs as BRCv (BRC repeat variant).

A Homology Model Predicts That BRCv Binds RAD51-like BRC—Structure predictions suggested that RECQL5-BRCv, like the BRCA2-BRC repeat, is largely devoid of regular secondary structure (31). A homology model for the RECQL5-BRCv repeat was generated in the Swissmodel server, using the RAD51-BRC4 structure (Protein Data Bank entry 1N0W) as the template (29). The model predicts that the conserved Phe and Ala side chains of the BRCv FXXA motif 1 may make contact with the hydrophobic pocket on the core catalytic domain of RAD51, part of the oligomerization interface, as seen in the RAD51-BRC4 structure (Fig. 2, A and C) (11). The LLDE motif 2 of BRCv is expected to bind a region of RAD51 distant from the oligomerization surface. The first two hydrophobic residues (Leu-700 and Leu-701) are predicted to occupy the same pocket occupied in RAD51 by Leu-1545 and Phe-1546 of BRCA2-BRC4, and the acidic residue in the fourth position (Glu-703) is expected to form a salt bridge with Arg-250 of RAD51, as seen for Glu-1548 of BRCA2-BRC4 (Fig. 2C) (11, 14). We note that the sequence that intervenes between the two BRCv motifs, predicted by the model to form a helix and a loop, is twice the length (25 amino acids) of that of the BRCA2-BRC repeat (12 amino acids) and therefore unique to the RECQL5-BRCv.

Both Motifs of the BRCv Are Needed for RECQL5-RAD51 Association—A previous study has shown that both motifs of BRCA2-BRC4 are required for RAD51 binding and BRC function (14). We investigated whether the two motifs of BRCv are similarly required for RECQL5 to associate with RAD51 by structure-guided mutagenesis, using the homology model described above. In motif 1, we substituted F666E or A669E to disrupt hydrophobic interactions at the predicted BRCv-RAD51 interface (Fig. 2C). In motif 2, we substituted L700E or L701E to disrupt the predicted hydrophobic interactions and E703A to abolish the predicted salt bridge with RAD51-R250 (Fig. 2C) (11, 14). We found that each mutation substantially reduced the amount of RAD51 that co-immunoprecipitated with RECQL5 (Fig. 2D, lanes 2–5). The results support the inference that both motifs are integral parts of a BRC repeat variant and indispensable for RAD51 interaction.

We noted that RECQL5 mutants in which only one motif of BRCv is mutated retained partial association with RAD51 (about 10–40%). We therefore generated several double mutants that simultaneously mutate both motifs and found that these mutants were more severely defective in RAD51 association (Fig. 2D, lanes 6–9). The data suggest that BRCv can bind RAD51 through either motif and that only when both motifs are inactivated is RAD51 binding abolished.

A Conserved Residue outside Motif 1 of BRCv Contributes to RAD51 Association—In addition to the two motifs, conserved residues next to motif 1 in BRCA2-BRC4 have also been shown to contribute to RAD51 association (11, 14). In particular, mutation of one of the hydrophobic residues, Val-1532, disrupts BRCA2-RAD51 association (32). We found that the corresponding residue of Val-1532 in BRCv is highly variable in RECQL5 from different species (Fig. 2A), indicating that this residue in BRCv is dispensable for RAD51 association. In contrast, BRCv has two highly conserved hydrophobic residues next to motif 1, Leu-672 and Met-673. Substitution of Leu-672 with Ala substantially reduced RECQL5-RAD51 association (supplemental Fig. S1), consistent with the notion that residues outside of motif 1 also contribute to RAD51 association.

Motif 1 of BRCv Is More Important than Motif 2 for Suppression of D-loop Formation—RECQL5 has been shown to possess anti-recombinase activity, evidenced by its ability to inhibit RAD51-mediated D-loop formation (20). This activity was later shown to be decreased in two mutants localized in motif 1: F666A, which substituted the conserved Phe in the FX(X)A consensus sequence, and Δ652–674, in which motif 1 was deleted (21). We studied whether one or both motifs of BRCv are required for the anti-recombinase activity of RECQL5, using the same D-loop assay (20). For this purpose, we expressed and purified several recombinant RECQL5 mutant proteins from E. coli that harbored mutations in either motif 1 (F666E) or 2 (L700E and E703E) or in both (F666E/L700E and F666E/E703A) (Fig. 3A). All three mutant proteins behaved like the wild type counterpart during purification and had wild-type levels of ATPase activity (Fig. 3B).

We found that whereas the wild type RECQL5 protein inhibited D-loop formation efficiently, the motif 1 mutant was deficient in this activity (Fig. 3, C–E). The result is in agreement with published data (21). In contrast, the results showed that the two motif 2 mutants are less affected in their D-loop inhibitory activity. As expected, the two variants with mutations in both motifs were more deficient in D-loop inhibitory activity (Fig. 3, C–E). These results indicate that although both motifs of the BRCv are required for optimal association between
FIGURE 2. A single BRC repeat variant in RECQL5 is essential for RAD51 interaction. A, sequence alignment showing similarities between BRCv of RECQL5 from different species and the eight BRC repeats of human BRCA2. Motif 1 and motif 2 are shown by red and green, respectively, with their consensus sequences shown at the top. The asterisks indicate a key conserved residue in the linker region that is also important for RAD51 association, but this residue is located at different positions between BRCv and BRC. A blue divider in the middle is used to highlight the difference in length of linker sequences between BRCA2-BRC and RECQL5-BRCv. The number of linker residues is shown in brackets. The species include human (HOMSA), mouse (MUSMU), chicken (GALGA), Xenopus (XENTR), fish (FUGRI), and Drosophila (DROME1 and DROME2). Notably, Drosophila RECQL5 has two potential BRCv, whereas that from other species has only one. B, sequence alignment of putative BRCv identified in four helicases (Srs2, Mph1, Sgs1, and Pif1) from different yeast species. The asterisks indicate the residues mutated to alanine. C, homology model of the RECQL5-BRC repeat. RAD51-BRC4 (BRCA2) (Protein Data Bank entry 1N0W) is shown overlaid with the homology model of RECQL5-BRCv. Cyan, RAD51; orange, BRCA2-BRC4; green, RECQL5-BRCv. Residues associated with motif 1 and motif 2 are shown in stick representations and labeled accordingly. D, IP-Western shows that RECQL5 with mutations in either motif 1 or 2 co-immunoprecipitated with reduced levels of RAD51, whereas that with mutations in both motifs almost completely lost RAD51 association. The numbers below lanes 1–5 indicate relative levels of RAD51 that co-immunoprecipitated with an indicated RECQL5 mutant, with the wild type protein being set as 1.0.
RECQL5 and RAD51, motif 1 is more essential for anti-recombinase function, with motif 2 seeming to play only a minor role.

Both Motifs of BRCv Are Required by RECQL5 to Suppress SCE—Using a trans-dominant negative assay in human HEK-293 cells, a small difference (about 15–20%) has been previously observed between a RECQL5 motif 1 mutant (F666A) and wild-type protein in the down-regulation of HR-dependent repair of double strand breaks (21). One caveat of this assay is that the exogenous protein needs to be overexpressed to a level significantly higher than that of the endogenous protein. To circumvent this requirement, we utilized RECQL5-knock-out chicken DT40 cells (18, 27) to investigate whether the conserved motifs of BRCv are needed for RECQL5 to promote genome stabilization in vivo. Because RECQL5 and BLM are functionally redundant in DT40 cells (RECQL5−/− single mutant cells lack obvious genome instability phenotypes), we studied functions of RECQL5 in RECQL5−/−/BLM−/− double mutant cells, which exhibit a higher SCE frequency and CPT sensitivity compared with BLM−/− single mutant cells (18, 27). We have previously shown that reintroduction of wild type RECQL5 protein into RECQL5−/−/BLM−/− cells restored the SCE frequency and CPT sensitivity to those of the BLM−/− cells, whereas reintroduction of RECQL5 mutants deficient in association with RNA polymerase II failed to fully rescue (27). Here we used the same RECQL5−/−/BLM−/− mutant cells to study whether various RECQL5-BRCv mutants (Fig. 4A) can correct these phenotypes.

All mutants were expressed at levels comparable with that of the wild-type protein (supplemental Fig. S2). In addition, all four variants with single-motif mutations in BRCv associated with RAD51 at reduced levels by IP-Western, and those with mutations in both motifs associated with little or no RAD51 (supplemental Fig. S2, lanes 1–8). These results are in agreement with the finding that both motifs of BRCv are required for normal association with RAD51 in human cells (Fig. 2D, lanes 6–9).

We noticed that the levels of RAD51 that associate with three single mutants (F666E, A669E, and L700E) were somewhat higher than those observed in human cells (compare Supplemental Fig. S2, lanes 2–4, with Fig. 2D, lanes 2–4). This could be due to the use of human proteins in chicken cells, so that the observed RECQL5-RAD51 association could be somewhat different compared with that in human cells.

As reported before (18, 27), the SCE level of RECQL5−/−/BLM−/− cells was found to be significantly higher than that of BLM−/− cells (28.8 versus 18.8), and this enhanced level of SCE was completely suppressed by reintroduction of wild type RECQL5 protein (Fig. 4, A and B). In this assay, lower SCE suppression efficiency correlates with a stronger protein defect, with the suppression efficiency of the wild type protein being set as 100%. Reintroduction of either motif 1 or 2 mutants partially suppressed the enhanced SCE levels of RECQL5−/−/BLM−/− cells. Suppression efficiency ranged from 34–47% for the two motif 1 mutants (F666E and A669E) to 67–81% for the two motif 2 mutants (L700E and E703A). Transfection of the variants with mutations in both motifs (F666E/L700E, A669E/L700E, and F666E/E703A) resulted in SCE suppression efficiency that was lower than that seen with single mutants; the level of SCE in cells that expressed these compound mutants was statistically indistinguishable from that of RECQL5−/−/BLM−/− cells (Fig. 4, A and B). These results are in accord with
the RAD51 binding data in Fig. 2, indicating that the RECQL5-RAD51 interactions mediated by both motifs of BRCv are required for optimal suppression of SCE. The observations that the two motif 1 mutants are more deficient in SCE suppression than the two motif 2 mutants correlate well with the D-loop inhibition data (Fig. 3) and suggest that motif 1 is more impor-

### Table 1: Summary of Different Human RECQL5 Mutants and Their Corresponding Activities

| RECQL5 Mutant | RAD51 Association | ATPase Activity | Pol IIa Binding | SCE Suppression Efficiency |
|---------------|-------------------|----------------|-----------------|---------------------------|
| WT            | +                 | ++             | +               | 100%                      |
| F666E         | +                 | ++             | +               | 34%                       |
| A609E         | +                 | +              | +               | 47%                       |
| L700E         |                  | +              | +               | 45%                       |
| E703A         |                  | +              | +               | 67%                       |
| F666E/L700E   |                  | +              | +               | 45%                       |
| A609E/L700E   |                  | +              | +               | 67%                       |
| F666E/E703A   |                  | +              | +               | 67%                       |
| E548D         |                  | +              | +               | 67%                       |
| K58R          |                  | +              | +               | 45%                       |
| K58R/F666E/E703A |              | +              | +               | 60%                       |

**Figure 4.** RECQL5 mutants deficient in RAD51 interaction are defective in suppression of SCE and resistance to CPT. 

**A.** Summary of different human RECQL5 mutants and their corresponding activities in association with RAD51, ATPase activity, Pol IIa binding, and suppression of SCE. Different RAD51 association is indicated as follows: ++, normal; +, reduced; −, nearly completely lost. SCE values are shown as a percentage. The suppression efficiency for the wild type protein was set to 100%. Lower suppression efficiency correlates with stronger defect. n.s, statistically not significantly different from the BLM−/−/RecQL5−/− cells.

**B.** Scatter plot showing the SCE levels of BLM−/−/RecQL5−/− DT40 cells complemented by the wild type and various mutants of RECQL5 as shown in A. Each point represents the total number of SCEs in a single mitotic spread. Conditions that show significant differences of p value < 0.05 or p value < 0.0001 are shown as one or three asterisks, respectively. The mean number of SCEs/cell is shown for each mutant, which was determined by examining chromosome spreads of three independent groups of metaphase cells (50 cells per group).

**C and D.** CPT sensitivity curves of BLM−/−/RecQL5−/− DT40 cells complemented with WT and different RECQL5 mutants, as indicated. Two different clones were tested for each mutant in order to ensure that the results are not due to clonal variation. Mean and S.D. (error bars) from three independent experiments are shown.
A BRC Repeat in the Anti-recombinase RECQL5

Potential BRCvs Are Present in Other HR Regulatory Proteins—One implication of our studies is that BRCVs may be utilized by proteins other than RECQL5 to regulate HR. When we searched protein databases with consensus sequences of the two BRCV motifs, we identified potential BRCV motifs in several HR regulatory proteins, including yeast helicases Sgs1, Srs2, Mph1, and Pif1 (see Fig. 2B). Interestingly, the first three helicases all have anti-recombinase activities similar to that of RECQL5, including disruption of RAD51-made D-loops and suppression of crossover recombination (20, 24, 25, 33, 34). The data imply that the predicted BRCV motifs in these helicases may play a similar role in modulating the interaction with Rad51 as does the BRCV motif of RECQL5.

A Predicted BRCV Motif in Srs2 Is Critical for RAD51 Association and Suppression of D-loop Formation—One of the putative BRCV motifs in Srs2 (see Fig. 2B) is located within the Rad51-binding region that has been previously mapped (residues 783–1038) (35). To study whether this BRCV is important for Srs2 to bind Rad51 and suppress HR, we mutated two residues that are highly conserved in RECQL5-BRCV motifs and critical for RECQL5 to bind RAD51: one within the predicted motif 1 (F837A) and the other just outside of the motif 1 (L844A) (see Fig. 2B). The Srs2 wild type and mutant proteins were expressed in E. coli, purified to near homogeneity (Fig. 6A), and analyzed for RAD51 association as described above for RECQL5. Both mutants had ATPase activity similar to that of the wild type protein (Fig. 6B), indicating that the proteins are folded properly. Importantly, the mutant L844A was strongly deficient in both Rad51 interaction (Fig. 6C) and inhibition of Rad51-mediated D-loop formation (Fig. 6, D and E), whereas the mutant F837A was largely normal in Rad51 association (Fig. 6C) but was modestly defective in suppression of D-loop formation at low protein concentrations (the suppression was about 70% for the wild type and 58% for the F837A mutant) (Fig. 6, D and E; compare lanes 5 and 3). Overall, these data support our prediction that a BRCV is present in Srs2, and this motif is critical for Srs2 to bind Rad51 and inhibit D-loop formation.

DISCUSSION

A BRC Repeat Variant in RECQL5 and Srs2 Mediates RAD51 Association—Although the BRC repeat had not been found in proteins other than BRCA2, we demonstrated that an HR regulatory protein, RECQL5, possesses a BRC repeat variant (BRCV) that resembles the BRCA2-BRC repeat in terms of structure and interaction motifs. Notably, both BRCV and BRC comprise two conserved motifs separated by a linker sequence, and the consensus sequence is identical for motif 1 and very similar for motif 2. Moreover, the two motifs in BRCV, as has been documented for BRC (14), are required for optimal RAD51 association; mutations in either motif reduce the ability of RECQL5 to bind RAD51, to inhibit RAD51-mediated D-loop formation, to suppress SCE, and to resist CPT-induced replication stress. Notably, using BRCV consensus sequences to search protein databases, we identified potential BRCV motifs in other HR regulatory proteins (Fig. 2B). We showed that a point mutant (L844A) in the predicted BRCV of Srs2 is strongly deficient in both Rad51 association and D-loop inhibition (Fig. 6). Our findings thus expand the role of the

BRCv Is Needed in Genome Maintenance Pathways Dependent on the Helicase Activity or the KIX Domain of RECQL5—We have previously shown that RECQL5 with mutations in either the helicase domain (K58R, which inactivates the helicase activity) or the KIX domain (E584D, which disrupts association with Pol IIa) were partially deficient in correcting the higher SCE level and CPT sensitivity of cells expressing the BRCv (27). We investigated whether the helicase- and KIX-dependent pathways require BRCV. For this purpose, we generated a mutant that compromises the BRCV and helicase function (K58R/F666E/E703A) and another that inactivates both the BRCV and KIX domain (E584D/F666E/E700A). IP-Western confirmed that these two mutants were as deficient in RAD51 binding (supplemental Fig. S2, lanes 5 and 6) and CPT hypersensitivity of RecQL5−/−/BLM−/− cells, whereas RECQL5 with mutations in both domains was completely deficient, suggesting that these two domains are needed for the integrity of different genome maintenance pathways (27). We investigated whether the helicase- and KIX-dependent pathways require BRCV. For this reason, we generated a mutant that compromises the BRCV and helicase function (K58R/F666E/E703A) and another that inactivates both the BRCV and KIX domain (E584D/F666E/E700A). IP-Western confirmed that these two mutants were as deficient in RAD51 association as the BRCV mutant (F666E/E703A). Importantly, neither the helicase nor the KIX domain mutation affected RAD51 binding (supplemental Fig. S2, lanes 9, 10, and 12).

We found that the SCE level and CPT sensitivity of RecQL5−/−/BLM−/− cells expressing the BRCV-helicase double mutant were higher (i.e., more functionally impaired) than those cells complemented by the helicase single mutant but were comparable with those cells complemented by the BRCV mutant (Fig. 5, A and B; also see Fig. 4A). Similarly, the SCE level and CPT sensitivity of cells expressing the BRCV-KIX double mutant were higher than those of cells complemented by the KIX single mutant but were comparable with those of cells complemented by the BRCV mutant (Fig. 5, A and C; also see Fig. 4A). These results suggest that both the helicase- and KIX domain-dependent genome maintenance pathways require BRCV to function.

Both Motifs of BRCv Are Required by RECQL5 to Promote Cellular Resistance to CPT-induced Replication Stress—We studied whether RECQL5 mutants carrying mutations in different motifs of BRCVs are defective in promoting resistance to CPT-induced replication stress. Consistent with our previous findings, introduction of human RECQL5 into RecQL5−/−/BLM−/− DT40 cells largely corrected the hypersensitivity of these cells to CPT (Fig. 4C) (27). Importantly, RECQL5 variants carrying mutations in either motif 1 (F666E and A669E) or motif 2 (L700E and E703A) were only partially active in rescuing the hypersensitivity to CPT, whereas variants carrying combined mutations in both motifs (F666E/E703A, F666E/L700E, A669E/L700E) were more deficient than single motif mutants in this assay (Fig. 4, C and D, and supplemental Fig. S3). These results correlate with the degree of RAD51 binding (Fig. 2D) by revealing that RECQL5 variants with single-motif mutations bound reduced amounts of RAD51 and partially supported CPT resistance, whereas variants with mutations in both motifs were more deficient in RAD51 binding and thus more defective in supporting CPT resistance. The results are also consistent with the SCE data and again suggest that both motifs of BRCV are required for the normal function of RECQL5 during genome stabilization.

Potential BRCvs Are Present in Other HR Regulatory Proteins—One implication of our studies is that BRCVs may be utilized by proteins other than RECQL5 to regulate HR. When we searched protein databases with consensus sequences of the two BRCV motifs, we identified potential BRCV motifs in several HR regulatory proteins, including yeast helicases Sgs1, Srs2, Mph1, and Pif1 (see Fig. 2B). Interestingly, the first three helicases all have anti-recombinase activities similar to that of RECQL5, including disruption of RAD51-made D-loops and suppression of crossover recombination (20, 24, 25, 33, 34). The data imply that the predicted BRCV motifs in these helicases may play a similar role in modulating the interaction with Rad51 as does the BRCV motif of RECQL5.

A Predicted BRCV Motif in Srs2 is Critical for RAD51 Association and Suppression of D-loop Formation—One of the putative BRCV motifs in Srs2 (see Fig. 2B) is located within the Rad51-binding region that has been previously mapped (residues 783–1038) (35). To study whether this BRCV is important for Srs2 to bind Rad51 and suppress HR, we mutated two residues that are highly conserved in RECQL5-BRCV motifs and critical for RECQL5 to bind RAD51: one within the predicted motif 1 (F837A) and the other just outside of the motif 1 (L844A) (see Fig. 2B). The Srs2 wild type and mutant proteins were expressed in E. coli, purified to near homogeneity (Fig. 6A), and analyzed for RAD51 association as described above for RECQL5. Both mutants had ATPase activity similar to that of the wild type protein (Fig. 6B), indicating that the proteins are folded properly. Importantly, the mutant L844A was strongly deficient in both Rad51 interaction (Fig. 6C) and inhibition of Rad51-mediated D-loop formation (Fig. 6, D and E), whereas the mutant F837A was largely normal in Rad51 association (Fig. 6C) but was modestly defective in suppression of D-loop formation at low protein concentrations (the suppression was about 70% for the wild type and 58% for the F837A mutant) (Fig. 6, D and E; compare lanes 5 and 3). Overall, these data support our prediction that a BRCV is present in Srs2, and this motif is critical for Srs2 to bind Rad51 and inhibit D-loop formation.

DISCUSSION

A BRC Repeat Variant in RECQL5 and Srs2 Mediates RAD51 Association—Although the BRC repeat had not been found in proteins other than BRCA2, we demonstrated that an HR regulatory protein, RECQL5, possesses a BRC repeat variant (BRCV) that resembles the BRCA2-BRC repeat in terms of structure and interaction motifs. Notably, both BRCV and BRC comprise two conserved motifs separated by a linker sequence, and the consensus sequence is identical for motif 1 and very similar for motif 2. Moreover, the two motifs in BRCV, as has been documented for BRC (14), are required for optimal RAD51 association; mutations in either motif reduce the ability of RECQL5 to bind RAD51, to inhibit RAD51-mediated D-loop formation, to suppress SCE, and to resist CPT-induced replication stress. Notably, using BRCV consensus sequences to search protein databases, we identified potential BRCV motifs in other HR regulatory proteins (Fig. 2B). We showed that a point mutant (L844A) in the predicted BRCV of Srs2 is strongly deficient in both Rad51 association and D-loop inhibition (Fig. 6). Our findings thus expand the role of the...
BRC repeat beyond BRCA2 and its orthologs. This strengthens the inference that the BRCv-mediated RAD51 association is important for HR regulation in general. Although the data presented herein indicate that the BRCv regulates interaction with Rad51 to mediate the anti-recombinase function of helicases, it remains an intriguing possibility that this motif may also promote Rad51 interaction in a prorecombination role under other circumstances.

We note that RECQL5 and several other vertebrate helicases (FBH1, RTEL1, and PARI) have been proposed to be functionally equivalent to yeast Srs2 (20, 36–38). Our finding that Srs2 contains a functional BRCv favors RECQL5 as the Srs2 equivalent in humans.

**BRCv and BRC Have both Common and Unique Features**—The structural and functional similarities between BRCv and BRC suggest that the two domains may engage the same epitope on RAD51. For example, motif 1 of BRCv is predicted to bind the same RAD51 oligomerization interface as motif 1 of BRC, which is expected to interfere with a crucial contact between RAD51 monomers to prevent RAD51 filament formation (11). On the other hand, motif 2 in BRCv is expected to interact with a pocket on RAD51 that is distant from the oligomerization surface (11, 14). In support of this model, RECQL5 motif 1 mutants are deficient in inhibiting RAD51-mediated D-loop formation, whereas RECQL5 motif 2 mutants have reduced, albeit still significant, inhibitory activity. Moreover, motif 1 mutants of RECQL5 are more defective than motif 2 mutants in SCE suppression. These data suggest that interaction mediated by motif 1 at the RAD51 oligomerization interface is more important in regulating RAD51 activity than interaction by motif 2 at the distant pocket. This may help to rationalize the observation that motif 1 is strictly conserved in RECQL5 orthologs through evolution, whereas motif 2 is not (Fig. 2A).

BRCv and BRC nevertheless differ from one another in several ways. First, the residues near motif 1 are different (Fig. 2A) between the two. In the BRCA2-BRC repeats, hydrophobic residues scattered in the linker between motif 1 and motif 2 are required for the interaction between the linker and RAD51 as the repeat wraps around RAD51 (11, 14, 32). This hydrophobic patch is not found in RECQL5-BRCv. Likewise, a pair of hydrophobic residues conserved in the RECQL5-BRCv immediately adjacent to the FXXA motif 1 are not found in the BRCA2-BRC repeats. One of these residues (Leu-672) is also conserved in Srs2-BRCv (Leu-844), and mutation of this residue in either RECQL5 or Srs2 substantially reduces RAD51 association. Thus, interactions with RAD51 outside the two primary motifs appear to be different for BRCv versus BRC. Second, the linker...
sequences between the two motifs are different; the length in BRC is constant (12 residues), whereas in BRCv is highly variable and also longer (18–25 residues) (Fig. 2A). The extra residues in BRCv are of unknown significance. Third, whereas BRC exists in multiple copies in human BRCA2, BRCv is present as a single copy in RECQL5 from most species. It was shown that BRC repeats within BRCA2 can be classified into two monomers from DNA in a processive fashion, it remains unclear how BRC repeats within BRCA2 can be classified into two motifs that have complementary functions and can work synergistically to activate HR (39). Speculatively, a single copy of BRCv may be sufficient for HR suppression, whereas cooperative interactions by multiple BRC repeats could be required for optimal activation of HR. Interestingly, Drosophila RECQL5 contains two putative BRCv repeats (Fig. 2A), hinting that BRCv may also function in tandem as seen in BRCA2-BRC.

We noted that the motif 1 mutant of Srs2-BRCv is only mildly defective in D-loop inhibition and is indistinguishable in Rad51 association compared with the wild type protein (Fig. 6). This differs from the motif 1 mutant of RECQL5 that is strongly defective in both assays (Fig. 2) (21). The data imply that Srs2 may be less dependent on motif 1-mediated Rad51 interactions compared with RECQL5.

Two Pathways Mediated by Helicase and KIX Domains Converge to Regulate BRCv-mediated Recombination—Previously, several functional domains were identified in RECQL5: the helicase domain that is involved in DNA translocation and the KIX and SRI domains that mediate the association with different forms of RNA Pol II (27, 40). The findings here add BRCv as a new distinct functional domain that enables RECQL5 to interact with RAD51. How do these different domains and their associated activities cooperate to accomplish RECQL5 functions? Our previously reported double mutant analyses have shown that the helicase and KIX domains act in independent pathways (27), whereas here we demonstrated that the BRCv is needed for the functional integrity of both pathways that are dependent on either the helicase or KIX domain. We suggest that BRCv-mediated RAD51 association may represent a common denominator of the two pathways that suppress SCE and confer resistance to CPT-induced replication stress (Fig. 5D). Although it seems likely that the helicase activity allows RECQL5 to translocate on DNA and dissociate RAD51 monomers from DNA in a processive fashion, it remains unclear how KIX affects BRCv-dependent RAD51 regulation. One possibility is that when the helicase/DNA translocase activity of RECQL5 is inactivated, the KIX-associated Pol II may recruit a backup helicase to power the translocation of RECQL5 on DNA in order to effect RAD51 removal.

In summary, our results suggest that the BRC repeat could be a general RAD51 regulatory module that can be used to either promote HR, as in the case of BRCA2, or repress HR, as in the case of RECQL5.

REFERENCES
1. Symington, L. S. (2002) Role of RAD52 epistasis group genes in homologous recombination and double-strand break repair. Microbiol. Mol. Biol. Rev. 66, 630–670, table of contents
2. Wu, L., and Hickson, I. D. (2006) DNA helicases required for homologous recombination and repair of damaged replication forks. Annu. Rev. Genet. 40, 279–306
3. Pâques, F., and Haber, J. E. (1999) Multiple pathways of recombination induced by double strand breaks in Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev. 63, 349–404
4. Sung, P., and Klein, H. (2006) Mechanism of homologous recombination. Mediators and helicases take on regulatory functions. Nat. Rev. Mol. Cell Biol. 7, 739–750
A BRC Repeat in the Anti-recombinase RECQL5

5. Jensen, R. B., Carreira, A., and Kowalczykowski, S. C. (2010) Purified human BRCA2 stimulates RAD51-mediated recombination. Nature 467, 678–683.

6. Thorslund, T., McIlwraith, M. J., Compton, S. A., Lekomtsev, S., Petronczki, M., Griffith, J. D., and West, S. C. (2010) The breast cancer tumor suppressor BRCA2 regulates the specific targeting of RAD51 to single-stranded DNA. Nat. Struct. Mol. Biol. 17, 1263–1265.

7. Liu, J., Doty, T., Gibson, B., and Heyer, W. D. (2010) Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA. Nat. Struct. Mol. Biol. 17, 1260–1262.

8. Carreira, A., Hilario, J., Amitani, I., Baskin, R. J., Shivji, M. K., Venkitaraman, A. R., and West, S. C. (2006) RECQL5 helicase with RAD51 facilitates its anti-recombinase activity. J. Biol. Chem. 281, 305–309.

9. Liu, J., Doty, T., Gibson, B., and Heyer, W. D. (2010) Human BRCA2 stimulates RAD51-mediated recombination by the PCNA-interacting protein PARI. Mol. Cell Biol. 30, 2460–2472.

10. Davies, A. A., Masson, J. Y., McIlwraith, M. J., Stasiak, A. Z., Stasiak, A., and West, S. C. (2008) RECQL5 promotes genome stabilization through two parallel mechanisms. Interacting with RNA polymerase II and acting as a helicase. Mol. Cell Biol. 30, 2460–2472.

11. Davies, A. A., Masson, J. Y., McIlwraith, M. J., Stasiak, A. Z., Stasiak, A., and West, S. C. (2008) RECQL5 promotes genome stabilization through two parallel mechanisms. Interacting with RNA polymerase II and acting as a helicase. Mol. Cell Biol. 30, 2460–2472.
A Variant of the Breast Cancer Type 2 Susceptibility Protein (BRC) Repeat Is Essential for the RECQL5 Helicase to Interact with RAD51 Recombinase for Genome Stabilization

M. Nurul Islam, Nicolas Paquet, David Fox III, Eloise Dray, Xiao-Feng Zheng, Hannah Klein, Patrick Sung and Weidong Wang

J. Biol. Chem. 2012, 287:23808-23818.
doi: 10.1074/jbc.M112.375014 originally published online May 29, 2012

Access the most updated version of this article at doi: 10.1074/jbc.M112.375014

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2012/05/29/M112.375014.DC1

This article cites 40 references, 23 of which can be accessed free at http://www.jbc.org/content/287/28/23808.full.html#ref-list-1